First tested the AI‑developed vaccine on humans

New vaccine created with the help of artificial intelligence passes first clinical trials

*Cambridge University in collaboration with its subsidiary DIOSynVax* developed a universal vaccine against sarbecoviruses. In early studies, the drug showed high safety and no serious side effects.

Key facts
The study was conducted using computer modeling and machine learning to create a “superantigen” – the active part of the vaccine. A human trial involved 39 healthy volunteers in the first round of testing. Goal: Provide long‑term protection against a wide range of viruses from the sarbecovirus family, including future mutations. Perspective: This approach could be scaled to other virus groups, such as Ebola.

What is a superantigen?
- Definition – a synthetic antigen that combines common features of all sarbecoviruses (COVID‑19, SARS, etc.).

- Advantage – it does not require selecting a specific strain; in theory it protects against viruses that have not yet emerged.

- New approach – traditionally vaccines use antigens from already known viruses. The superantigen frees scientists from the “constant search cycle” of circulating variants.

What next?
In the second phase of clinical trials, the plan is to test how well the vaccine induces protective immunity in a broader and more diverse population. This will allow assessment of its real effectiveness across varied demographic groups.

Industry context
In recent years, major pharmaceutical companies (Eli Lilly, AstraZeneca, Novartis) have struck multi‑billion dollar deals with firms using AI for drug development. An example is the American startup Recursion, which went public in 2021 and was valued at over $5 billion.

Conclusion:

The first successful launch of a vaccine entirely designed with artificial intelligence opens new horizons for fighting rapidly changing viruses. If subsequent trials confirm its effectiveness, this approach could become the standard for creating universal protective measures against entire families of viruses.